| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Millendo Therapeutics, Inc. | Director | Common Stock | 580K | $1.37M | $2.36 | Jun 25, 2021 | By Quan Venture Fund I, L.P. |
| Design Therapeutics, Inc. | Director | Stock Option (right to buy) | 15K | May 31, 2023 | Direct | ||
| NextCure, Inc. | Director | Stock Option (Right to Buy) | 14.3K | Jun 24, 2021 | Direct | ||
| Tempest Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 6.64K | Jul 1, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | May 31, 2023 | 1 | $0 | 4 | Jun 2, 2023 | Director |
| DSGN | Design Therapeutics, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 16, 2022 | Director |
| DSGN | Design Therapeutics, Inc. | Mar 18, 2022 | 4 | -$11.3M | 4 | Mar 22, 2022 | Director |
| TPST | Tempest Therapeutics, Inc. | Jul 1, 2021 | 1 | $0 | 4/A | Sep 20, 2021 | Director |
| TPST | Millendo Therapeutics, Inc. | Jun 25, 2021 | 1 | $0 | 4 | Jun 29, 2021 | Director |
| TPST | Millendo Therapeutics, Inc. | Jun 25, 2021 | 0 | $0 | 3 | Jun 29, 2021 | Director |
| NXTC | NextCure, Inc. | Jun 24, 2021 | 1 | $0 | 4 | Jun 28, 2021 | Director |